Alright so FDA better approve PP405 as fast as they approved covid vaccine
    7/24/2025

    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    At a glance
    In this general discussion post, the primary subjects mentioned are
    💧 Minoxidil (topical)
    💧 PP405 (topical) 4 weeks
    the tone is 😐 neutral with promising early results.

    Other terms

    PP405 is a potential hair loss treatment showing promising early results, with hopes for market release by 2028, but skepticism remains due to inconclusive data and past disappointments with similar products. Current treatments like Minoxidil and Finasteride have side effects, leading some to anticipate PP405 as a safer alternative, though its effectiveness compared to placebo is debated.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community What new hair-loss treatments actually look exciting right now (Oct 2025)

       171 upvotes 11 months ago
      New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

      community The future of hair loss drugs.

       34 upvotes 7 months ago
      Clascoterone 5% and PP405 are being discussed as potential future treatments for hair loss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hair loss, but a complete cure remains elusive.

      community Can we get a reality check on PP405?

       79 upvotes 11 months ago
      PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

    Related Research

    6 / 6 results

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

      research Emerging pharmacotherapies for Androgenetic Alopecia

      June 2026 in “Expert Opinion on Pharmacotherapy”
      This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.